References
- Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. (2010). Critical care and the global burden of critical illness in adults. Lancet 376:1339–46
- Angelone T, Mazza R, Cerra MC. (2012). Chromogranin-A: a multifaceted cardiovascular role in health and disease. Curr Med Chem 19:4042–50
- Angus DC, Wax RS. (2001). Epidemiology of sepsis: an update. Crit Care Med 29:S109–16
- Annane D, Aegerter P, Jars-Guincestre MC, et al. (2003). Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168:165–72
- Arora S, Singh P, Singh PM, Trikha A. (2014). Procalcitonin levels in survivors and non survivors of Sepsis: systematic review and meta-analysis. Shock 43:212--21
- Bone RC, Balk RA, Cerra FB, et al. (1992). Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101:1644–55
- Braber A, Van Zanten AR. (2010). Unravelling post-ICU mortality: predictors and causes of death. Eur J Anaesthesiol 27:486–90
- D'amico MA, Ghinassi B, Izzicupo P, et al. (2014). Biological function and clinical relevance of chromogranin A and derived peptides. Endocr Connect 3:R45–54
- Dellinger RP, Levy MM, Rhodes A, et al., Surviving Sepsis Campaign Guidelines Committee Including the Pediatric S (2013). Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637
- Donadello K, Scolletta S, Taccone FS, et al. (2014). Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 29:144–9
- Gaieski DF, Edwards JM, Kallan MJ, Carr BG. (2013). Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med 41:1167–74
- Jawad I, Luksic I, Rafnsson SB. (2012). Assessing available information on the burden of sepsis: global estimates of incidence, prevalence and mortality. J Glob Health 2:010404
- Knaus WA, Draper EA, Wagner DP, Zimmerman JE. (1985). APACHE II: a severity of disease classification system. Crit Care Med 13:818–29
- Lagu T, Rothberg MB, Shieh MS, et al. (2012). Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 40:754–61
- Linde-Zwirble WT, Angus DC. (2004). Severe sepsis epidemiology: sampling, selection, and society. Crit Care 8:222–6
- Mortensen EM, Halm EA, Pugh MJ, et al. (2014). Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA 311:2199–208
- Rosjo H, Nygard S, Kaukonen KM, et al. (2012). Prognostic value of chromogranin A in severe sepsis: data from the FINNSEPSIS study. Intensive Care Med 38:820–9
- Schneider F, Bach C, Chung H, et al. (2012). Vasostatin-I, a chromogranin A-derived peptide, in non-selected critically ill patients: distribution, kinetics, and prognostic significance. Intensive Care Med 38:1514–22
- Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, et al. (2013). Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med 39:1945–52
- Zhang D, Lavaux T, Sapin R, et al. (2009). Serum concentration of chromogranin A at admission: an early biomarker of severity in critically ill patients. Ann Med 41:38–44
- Zhang D, Lavaux T, Voegeli AC, et al. (2008). Prognostic value of chromogranin A at admission in critically ill patients: a cohort study in a medical intensive care unit. Clin Chem 54:1497–503